Egf Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| EGF Protein | |
|---|---|
| Protein Name | Epidermal Growth Factor |
| Gene | EGF |
| UniProt ID | P01133 |
| PDB IDs | 1EGF, 1NQL, 2JV2 |
| Molecular Weight | 6.2 kDa (protein core) |
| Subcellular Localization | Cell surface, Extracellular |
| Protein Family | EGF family |
The EGF (Epidermal Growth Factor) protein is a 53-amino acid mitogenic peptide that binds to the EGF receptor (EGFR/HER1), a receptor tyrosine kinase. EGF binding induces EGFR dimerization and autophosphorylation, activating downstream signaling cascades including MAPK/ERK, PI3K/AKT, and PLCgamma pathways. In the nervous system, EGF promotes neuronal survival, stimulates neurogenesis, and enhances synaptic plasticity. EGF has shown neuroprotective effects in experimental models of Parkinson's disease, Alzheimer's disease, and stroke, making it a potential therapeutic candidate for neurodegenerative disorders.
Epidermal growth factor (EGF) is a mitogenic peptide that stimulates cell proliferation and differentiation through EGFR activation.
EGF is a 53-amino acid growth factor containing six conserved cysteine residues that form three disulfide bonds (Cys6-Cys20, Cys14-Cys31, Cys33-Cys42), creating three β-hairpin loops. The protein has a tight, compact structure essential for receptor binding. EGF binds to EGFR with high affinity (Kd ~ 1 nM) by engaging EGFR domains I and III.
EGF binds to the EGF receptor (EGFR/HER1) causing receptor dimerization and activation of intrinsic tyrosine kinase activity. This triggers downstream signaling via MAPK/ERK, PI3K/AKT, and PLCγ pathways. EGF promotes neuronal survival, stimulates neurogenesis in the subventricular zone and hippocampus, enhances synaptic plasticity, and has neuroprotective effects in models of PD, stroke, and AD. EGF also promotes gliogenesis.
EGF has neuroprotective potential in AD (enhances cholinergic function), PD (protects dopaminergic neurons), and stroke (reduces infarct size). Reduced EGF signaling is implicated in aging-related cognitive decline. EGF is being explored for regenerative therapies in peripheral neuropathy.
Recombinant human EGF is used clinically for wound healing (topical). EGFR inhibitors (gefitinib, erlotinib) are used in cancer but may impair neurogenesis. EGFR agonists are being investigated for neurodegenerative diseases. EGF delivery to the brain remains challenging due to BBB. Intranasal delivery is being explored.
EGF protein has significant clinical relevance in neurodegenerative diseases. In Alzheimer's disease, EGF and EGFR signaling are altered, with decreased EGFR expression in the hippocampus. EGF has been investigated as a potential therapeutic agent for neurodegenerative conditions due to its neurotrophic effects. Clinical trials have explored EGF delivery for Parkinson's disease and other neurodegenerative disorders.
Current research focuses on understanding EGF's role in neuroprotection, developing EGF-based therapies that can cross the blood-brain barrier, investigating EGF combination therapies with other neurotrophic factors, and exploring gene therapy approaches for EGF delivery to the brain.
The study of Egf Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.